Humanized CD40 Mouse Models for Accurate Immune Response Simulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional drug development methods for immune-related diseases and cancers face challenges due to the inability of conventional animal models to accurately replicate human immune responses and tumor microenvironments, leading to high failure rates and costly clinical trials.
Innovation Solution
Development of genetically modified animal models that express human or chimeric CD40, allowing for the study of CD40 function and the evaluation of anti-CD40 antibodies in a more human-relevant context, facilitating drug screening and cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional animal models are used for drug screening, then the research process is simple and cost-effective, but the results cannot accurately reflect human immune responses and tumor microenvironments
Solution Approach 1:
The patent creates humanized mouse models by replacing the endogenous mouse CD40 gene with the human CD40 gene, allowing the mouse to express human CD40 protein. This copying of the human gene into the animal model enables the model to reflect human immune responses and tumor microenvironment interactions more accurately, resolving the contradiction between measurement precision and device complexity.
Solution Approach 2:
The patent modifies the genetic parameter of the mouse model by introducing human CD40 gene sequences at the endogenous CD40 locus. This parameter change (from mouse to human gene sequence) fundamentally alters the protein expression characteristics, enabling the model to better represent human disease states while maintaining the overall animal model framework.
2Reliability
If in vitro screening approaches are used, then the experimental setup is simple and controllable, but the results fail to account for body environment factors such as tumor microenvironment and immune cell interactions
Solution Approach 1:
The humanized mouse model serves as an intermediary system between in vitro experiments and human clinical trials. It provides a living model that incorporates complex body environment factors including tumor microenvironment, stromal cells, extracellular matrix components, and immune cell interactions, thereby improving the reliability of drug development results while adding experimental complexity.
Solution Approach 2:
The patent replaces simple in vitro mechanical screening systems with a living in vivo animal model system. This substitution enables the study of drug effects in the context of complex biological interactions within the whole organism, improving result reliability by accounting for physiological factors that cannot be replicated in vitro.
3Measurement precision
If conventional animal models are used for in vivo pharmacological testing, then the experiment is feasible with standard animals, but the test results do not reflect real disease state and targeting site interactions
Solution Approach 1:
The patent copies the human CD40 gene into the mouse genome at the endogenous CD40 locus, creating a humanized mouse model. This copying process enables the model to accurately reflect human disease states and targeting site interactions, particularly for CD40-targeted therapies, while maintaining the feasibility of using mouse models for experimentation.
Solution Approach 2:
The patent applies gene targeting technology to specifically modify only the CD40 gene region while keeping the rest of the mouse genome intact. This segmentation approach allows precise introduction of human CD40 at the endogenous locus, achieving accurate disease state reflection without the complexity of completely replacing the animal model.
4Measurement precision
If humanized animal models are developed, then the accuracy of human immune response simulation is improved, but the development time and cost increase
Solution Approach 1:
The patent employs established gene targeting techniques and existing humanized mouse platforms to rapidly introduce the human CD40 gene. By using pre-developed methodologies and infrastructure, the model can be created more efficiently, reducing the time loss associated with developing humanized models from scratch while maintaining high accuracy in human immune response simulation.
Data Source
AI summary
The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.